Opinion|Videos|November 12, 2024
Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials
Key Takeaways
- Fezolinetant's approval was based on SKYLIGHT 1, 2, and 4 trials, which were randomized, double-blind, and placebo-controlled.
- The trials focused on women with moderate to severe vasomotor symptoms, evaluating fezolinetant's safety and efficacy.
Panelists discuss the methodologies of the SKYLIGHT 1, SKYLIGHT 2, and SKYLIGHT 4 trials that supported the approval of fezolinetant for moderate to severe vasomotor symptoms (VMS) and examine the key safety and efficacy results derived from these studies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- (SMITH) The approval of fezolinetant for moderate to severe VMS was based on the
SKYLIGHT 1 ,SKYLIGHT 2 , andSKYLIGHT 4 trials. Briefly describe the methodology of these studies. - (FIFFICK) What were the key safety and efficacy results from the SKYLIGHT studies?
Advertisement
Related to this article
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.
Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
3
Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD
4
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
5